Q50JE5 AF NFT

Angiotensin-converting enzyme

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeiavaowd7pebdpor6fvxz4aekubza6hqve7qbl6sl6cgjxrsahz6pm/metadata.json
IPFS of structure file: 
bafybeifz4wh5rhbjaerqbc4k2k34s44iiuhwyehtuzb62cjlhhmahhfttu/AF-Q50JE5-F1-model_v2.pdb
First NFT owner address (eip-55): 
0xe98bf0c02d2A46E3299A9930210B6C72162719bF
First NFT owner address (bech32): 
genesis1ax9lpspd9frwx2v6nyczzzmvwgtzwxdl6avkay
Current NFT ID #5749 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1_w

NFT id:
5749
Accession (UniProt):
Q50JE5
Name::
Angiotensin-converting enzyme
Experimental Method:
Predicted structure
Sequence source:
MESOCRICETUS AURATUS

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT Q50JE5 research and analysis (ICN3D with VR)

FASTA sequences

>sp|Q50JE5|ACE_MESAU Angiotensin-converting enzyme OS=Mesocricetus auratus OX=10036 GN=Ace PE=2 SV=1 MGAASGQRGQGPPSPLLLLWLSLLLLLLPPSPAPALDPGLQPGNFSADEIGAHLFAESYNSSAEQVIFQSTVASWAYDTNMTEENARLQEEAELIWQEFAEVWGKKAKELFDAIRQNFTDSKLRRVIETIRTLGPANLPLARRQQYNSLQNNMNRIYSTSKVCLPNKTATCWSLEPELTNILASSRSYAKLLFAWESWHDVVGIPLKPLYQDFTALSNEAYKQDGFSDTGAYWRSAYDSPSFEETLEHLYHQLEPLYLNLHAYVRRALHRRYGDKYINLRGPIPAHLLGDMWAQSWDNIYDMVVPFPNKPNLDVTNTMVQKGWNVTHMFRVAEEFFTSMGLSPMPPEFWAESMLEKPTDGREVVCHASAWDFFNRKDFRIKQCTRITMEQLSTVHHEMGHVQYYLQYKDLTVPLRRGANPGFHEAIGDVLALSVSTPAHLHKIGLLDRVANDLESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGHTPPSRYNFDWWYFRTKYQGICPPVVRNETHFDAGAKFHIPSGTPYIRYFVSFILQFQFHQALCKEAGHQGPLHQCDIYQSTQAGAKLQRVLQAGYSRPWQEVLKEMVGSDTLDAQALLEYFQPVIRWLQEQNQRNGEVLGWPEYQWRPPLPDNYPEGIDLVTDETEAERFVEEYDRTARVLWNEYAEANWQYNTNITLEASKILLQKNKKVANHTLKYGTLAKKFDVSNFQNYTIKRIIKKVQNMDRAVLPPKELEEYNQILMDMETTYSIANVCYLNGTCLHLEPDLTNVMATSRKYEELLWVWKSWRDKVGRAILPLFPKYVELSNKIAHLNGYADGGDSWRSSYESKSLEQDLEQLYQELQPLYLNLHAYVRRSLHRHYGSQHINLDGPIPAHLLGNMWAQTWSNIYDLVAPFPSAPNLDATEAMIKQGWTPRRIFKEADDFFTSLGLLPVSEEFWNKSMLEKPGDGREVVCHASAWDFYNGKDFRIKQCTSVNMEDLVIAHHEMGHIQYFMQYKDLPVTFREGANPGFHEAIGDVLALSVSTPKHLHSLNLLSSEGGGYEHDINFLMKMALDKIAFIPFSYLIDQWRWRVFDGSITKENYNQEWWSLRLKYQGLCPPVPRSQDDFDPGSKFHVPANVPYIRYFVSFIIQFQFHEALCRAAGHTGPLHKCDIYQSKEAGKLLADTMKMGYSKPWPEAMKLITGQPNMSASAMMNYFKPLTEWLVTENRRHGETLGWPEYNWTPNTARSEGPFPESGRVNFLGMYLEPQQARVGQWVLLFLGVSLLVATLGLTHRLFSIRQHGHSLHRPHRGPQFGSEVELRHS